INTRODUCTION AND HYPOTHESIS: The purpose of this study is to compare retropubic tension-free vaginal tape (TVT) with transobturator out-in TOT and in-out TVT-O for female stress urinary incontinence. Uroflow rate was primary; continence rates, quality of life (QoL) and complication pattern were secondary endpoints. METHODS: A prospective randomised trial with 2:1:1 randomisation at two Swiss teaching hospitals. Patients were followed up at 12 months. RESULTS:Eighty TVT, 40 transobturator tape (TOT) and 40 TVT-O were randomised. At 12 months, there was no difference in Qmax among the groups. Continence was comparable (≥ 89%). QoL was improved significantly in all groups (P < 0.05). Five vaginal tape exposures occurred (one TVT, four TOT, zero TVT-O; P = 0.028). Two percent (1/52) of sexually active patients after TVT, 17% (5/29) after TOT, but 0% (0/25) after TVT-O reported de novo female sexual dysfunction (P = 0.011). We considered this clinically important enough to stop enrolment. CONCLUSIONS: There was no difference for Qmax at 12 months between TVT, TOT and TVT-O. Female sexual dysfunction and tape exposure may be higher with a transobturator tape.
RCT Entities:
INTRODUCTION AND HYPOTHESIS: The purpose of this study is to compare retropubic tension-free vaginal tape (TVT) with transobturator out-in TOT and in-out TVT-O for female stress urinary incontinence. Uroflow rate was primary; continence rates, quality of life (QoL) and complication pattern were secondary endpoints. METHODS: A prospective randomised trial with 2:1:1 randomisation at two Swiss teaching hospitals. Patients were followed up at 12 months. RESULTS: Eighty TVT, 40 transobturator tape (TOT) and 40 TVT-O were randomised. At 12 months, there was no difference in Qmax among the groups. Continence was comparable (≥ 89%). QoL was improved significantly in all groups (P < 0.05). Five vaginal tape exposures occurred (one TVT, four TOT, zero TVT-O; P = 0.028). Two percent (1/52) of sexually active patients after TVT, 17% (5/29) after TOT, but 0% (0/25) after TVT-O reported de novo female sexual dysfunction (P = 0.011). We considered this clinically important enough to stop enrolment. CONCLUSIONS: There was no difference for Qmax at 12 months between TVT, TOT and TVT-O. Female sexual dysfunction and tape exposure may be higher with a transobturator tape.
Authors: Giacomo Novara; Walter Artibani; Matthew D Barber; Christopher R Chapple; Elisabetta Costantini; Vincenzo Ficarra; Paul Hilton; Carl G Nilsson; David Waltregny Journal: Eur Urol Date: 2010-04-23 Impact factor: 20.096
Authors: Sue Ross; Magali Robert; Cheryl Swaby; Lorel Dederer; Doug Lier; Selphee Tang; Penny Brasher; Colin Birch; Dave Cenaiko; Tom Mainprize; Magnus Murphy; Kevin Carlson; Richard Baverstock; Philip Jacobs; Tyler Williamson Journal: Obstet Gynecol Date: 2009-12 Impact factor: 7.661
Authors: Karl Tamussino; Engelbert Hanzal; Dieter Kölle; Ayman Tammaa; Oliver Preyer; Wolfgang Umek; Vesna Bjelic-Radisic; Hermann Enzelsberger; Peter F J Lang; George Ralph; Paul Riss Journal: Am J Obstet Gynecol Date: 2007-12 Impact factor: 8.661
Authors: P Costa; P Grise; S Droupy; F Monneins; C Assenmacher; P Ballanger; J F Hermieu; V Delmas; L Boccon-Gibod; C Ortuno Journal: Eur Urol Date: 2004-07 Impact factor: 20.096
Authors: Jerry G Blaivas; Rajveer S Purohit; Matthew S Benedon; Gabriel Mekel; Michael Stern; Mubashir Billah; Kola Olugbade; Robert Bendavid; Vladimir Iakovlev Journal: Nat Rev Urol Date: 2015-08-18 Impact factor: 14.432